Keith J. Killian
National Institutes of Health · 47 works · 1,476 citations · h-index 13
Top works
- Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
- Genomic aberrations in pediatric diffuse intrinsic pontine gliomas
- A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors
- Physicochemically modified silicon as a substrate for protein microarrays
- Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
- Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors
- Primary neuroendocrine tumors of the kidney: morphological and molecular alterations of an uncommon malignancy
- Histone Demethylase Jumonji D3 (JMJD3) as a Tumor Suppressor by Regulating p53 Protein Nuclear Stabilization
- A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.
- CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model
- Fractionation of Serum Components Using Nanoporous Substrates
- Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers
- ERBB4 Mutation Analysis: Emerging Molecular Target for Melanoma Treatment
- NF2 mutation-driven renal cell carcinomas (RCC): A comprehensive genomic profiling (CGP) study.
- Custom (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies) trial.
- Somatic VHL Mutation in a Patient With MEN1-Associated Metastatic Pancreatic Neuroendocrine Tumor Responding to Sunitinib Treatment: A Case Report
- A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (guadecitabine), in children and adults with wild type GIST, pheochromocytoma and paraganglioma associated with succinate dehydrogenase deficiency and HLRCC-associated kidney cancer.
- Comprehensive genomic profiling (CGP) of carcinoma of unknown primary origin (CUP): Retrospective molecular classification of potentially eligible patients (pts) for targeted or immunotherapy treatment (tx) using the prospective CUPISCO trial’s criteria
- Primary versus metastatic intrahepatic cholangiocarcinoma: A comparative comprehensive genomic profiling (CGP) study.
- COXEN prediction of antineoplastic drug sensitivity in bladder cancer patients.